A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
Chutes & Ladders—Pfizer RNA leader runs to Replicate
Chutes & Ladders—Pfizer RNA leader runs to Replicate
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts
Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug
Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug
Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability
Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability
Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic
BIOTECH Pfizer-backed Triana scores 20M series B to take molecular glue degrader into clinic By James Waldron Dec 3, 2025 10:35am molecular glue series B Pfizer Venture...
<a href="https://www.fiercebiotech.com/biotech/pfizer-details-phase-3-data-mrna-flu-vaccine" hreflang="en">Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3</a>
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to...
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page